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The inhibition of triosephosphate isomerase (TPI) in glycolysis by the pyruvate
kinase (PK) substrate phosphoenolpyruvate (PEP) results in a newly discovered
feedback loop that counters oxidative stress in cancer and actively respiring
cells. The mechanism underlying this inhibition is illuminated by the co-crystal
structure of TPI with bound PEP at 1.6 Å resolution, and by mutational studies
guided by the crystallographic results. PEP is bound to the catalytic pocket of
TPI and occludes substrate, which accounts for the observation that PEP com-
petitively inhibits the interconversion of glyceraldehyde-3-phosphate and
dihydroxyacetone phosphate. Replacing an isoleucine residue located in the cat-
alytic pocket of TPI with valine or threonine altered binding of substrates and
PEP, reducing TPI activity in vitro and in vivo. Confirming a TPI-mediated
activation of the pentose phosphate pathway (PPP), transgenic yeast cells expres-
sing these TPI mutations accumulate greater levels of PPP intermediates and
have altered stress resistance, mimicking the activation of the PK–TPI feed-
back loop. These results support a model in which glycolytic regulation
requires direct catalytic inhibition of TPI by the pyruvate kinase substrate PEP,
mediating a protective metabolic self-reconfiguration of central metabolism
under conditions of oxidative stress.2. Introduction
With the challenge of surviving in a constantly changing environment, cells have
evolved mechanisms to flexibly regulate metabolism [1,2]. An important and
dynamically regulated metabolic pathway is glycolysis, an ancient chemical
route of carbohydrate utilization that produces ATP, NADH and intermediate
metabolites for the synthesis of nucleotides, fattyacids and amino acids. Glycolysis
is mainly regulated through feedback and feed-forward cycles involving its inter-
mediate metabolites. These cycles sustain intermediates while preventing their
accumulation to toxic levels and are responsible for the oscillating behaviour of
glycolytic reactions [3–6]. Moreover, this enzymatic regulation is important for
maintaining the balance of metabolism during changes in cell growth or environ-
ment [1,2]. As an example, the increased need for the redox cofactor NADPH
during oxidative stress caused upon hydroperoxide exposure is met by diverting
Table 1. Crystallographic data collection and refinement statistics. The PDB
deposition code for model and structure factors of TPI – PEP is 4OWG.
data collection
wavelength (Å) 0.9795
resolution (Å) 43.1 – 1.55
(high-resolution shell) 1.63 – 1.55
Rmerge 0.086 (0.314)




unit cell (a, b, c (Å);
a,b,g (deg))
a ¼ 36.85, b ¼ 72.07, c ¼ 161.20,
a ¼ b ¼ g ¼ 90
space group P212121
refinement
R (working set) 0.1665
Rfree (test set) 0.2032
RMS deviations
bond lengths (Å) 0.0195
bond angles (Å) 1.9061
Ramachandran statistics
% of residues in
allowed regions
465 (96.27%)
% of residues in
generously allowed
14 (2.90%)









2glycolytic flux into the pentose phosphate pathway (PPP). This
transition is rapidly inducible by metabolic inhibition of
glycolysis, changes in the activity of glucose 6-phosphate dehy-
drogenase (the first enzyme of the oxidative PPP), followed by
transcriptional control during mid- to long-term adaptation to
oxidative conditions [7–10].
A similar mechanism acts to prevent an accumulation of
oxidizing metabolites in cancer cells or cells that respire at
high rates. These frequently possess a higher activity of the
PPP to balance the greater demand for NADPH by the anti-
oxidant machinery and to compensate for the increased pro-
duction of reactive oxygen species [11,12]. Current findings
have highlighted the importance of the terminal glycolytic
enzyme pyruvate kinase (PK) to achieve the regulation of gly-
colysis and the PPP. Low activity of PK has been found in
cancer and rapidly proliferating cells, and in yeast cells with
high respiration activity [13,14]. More recently, it has been pro-
posed that cancer cells profit from the loss of the PKM2 gene
during tumour formation [15]. Reduced PK activity caused
accumulation of its substrate, phosphoenolpyruvate (PEP),
which correlates with an increased activity of the PPP [14,16],
and increased oxidant tolerances of both mammalian and
yeast cells [11,14]. It has been observed that PEP is an inhibitor
of another metabolic redox regulator, triosephosphate isomerase
(TPI or TIM, EC 5.3.1.1) [17,18]. In its glycolytic role, TPI is
regarded as a near-perfect catalyst because its catalytic speed
in vitro only depends on the rate of diffusion of its substrates
[19]. In vivo, TPI interconverts dihydroxyacetone phosphate
(DHAP) and glyceraldehyde-3-phosphate (G3P) to prevent an
accumulation of DHAP [19,20]. Reduced activity of TPI in
yeast and Caenorhabditis elegans leads to a partial inhibition
of glycolysis but is beneficial during oxidative stress, as it
increases the concentration of PPP metabolites and stress toler-
ance in both species [7,21]. We have shown previously that the
increased oxidative stress resistance of PK mutants is attributable
to TPI as well. In yeast cells expressing mutant TPI with lowered
activity, PK failed to increase stress resistance, while a deletion of
the first enzyme of the oxidative PPP, glucose 6-phosphate dehy-
drogenase (G6PDH, ZWF1), leads to protein and mitochondrial
oxidative damage in a PK-dependent manner [14].
To understand how PEP affects TPI activity, we generated a
co-crystal structure of the enzyme in complex with PEP at 1.6 Å
resolution. We find that PEP directly interacts with TPI by
binding into the catalytic pocket of the enzyme and outcom-
petes the substrates from their binding position. Moreover,
the structural data reveal that PEP interacts with the conserved
Ile170, a residue which when mutated is associated with TPI
deficiency in humans [22], and in yeast affects response to oxi-
dative stress [7,23] and PK function [14]. We use this mutant
and others inferred from the crystallographic structure to
define the kinetics and stability properties of TPI upon PEP
binding. We demonstrate that the in vivo consequence of com-
petitive TPI inhibition is the activation of the PPP and altered
stress resistance.3. Results and discussion
3.1. Structure of the triosephosphate isomerase –
phosphoenolpyruvate complex
TPI is a ubiquitous enzyme with homologues found throughout
all kingdoms of life [20,24] and that in human populationspossesses only a minimum of sequence divergence [25]. To
study the TPI–PEP interaction, we co-crystallized PEP and
rabbit TPI, which differs from human TPI in four non-conserved
residues only (electronic supplementary material, figure S1).
The structure was solved by molecular replacement and refined
at 1.55 Å resolution (table 1). The asymmetric unit contains a
homodimer of TPI (figure 1a). Each protomer contains eight
a-helices on the outside and eight parallel b-strands on the
inside, forming a typical TIM-barrel [26]. Comparison of
TPI-PEP with a previously reported structure of rabbit muscle
apo TPI [27] shows that the active site loops are in the closed con-
formation in both subunits. The electron density map gave a
clearly defined and unambiguous shape for PEP bound to the
active sites of both subunits (figure 1a,c). Active site residues
engage PEP and make similar interactions to those observed
for the TPI substrate DHAP (figures 1b and 2a,b; a stereo-
scopic illustration is given in figure 1c) [28]. For substrate
conversion, TPI employs a catalytic triad consisting of the resi-
dues Lys13, His95 and Glu165 [27], whereas PEP is in contact
with the catalytically active residue Lys13 and the active site
residues Gly232, Gly233, Gly171, Ser211 and Asn11 (figure 2).








Figure 1. Co-crystal structure of TPI with bound PEP. (a) Schematic of the TPI –
PEP crystallographic structure. PEP locates in the active centre of both subunits in
the asymmetric TPI dimer. (b) The catalytic pocket of TPI bound to PEP. Catalytic
residues are highlighted in yellow, PEP in red, isoleucine 170 in green. (c) Stereo-
scopic illustration of the PEP binding site environment including a difference map
in which PEP has been removed from the model and was refined against the
experimental data for five cycles. The map has been contoured at 4 s.d. and





catalytic pocket of TPI and competes with the substrates for
binding with catalytic residues (figure 2c).
3.2. Structure – function analysis of the triosephosphate
isomerase – phosphoenolpyruvate interaction
We observed that PEP is in direct contact with a conserved
isoleucine at position 170. A human TPI allele mutant for this
residue (Ile170Val) has been found in a rare variant in the
human genetic disorder TPI deficiency. This mutation translates
into a mutant TPI with reduced catalytic activity [21,22]. TPI
deficiency manifests as recessive autosomal multi-system dis-
order, which is caused by structural defects in the TPI enzyme
[29]. Based on the crystallographic information, we predicted
two further residue exchanges to affect PEP binding and gener-
ated two constructs encoding for TPILys13Arg as well as
TPIIle170Thr. Lys13 is known to be required for the catalytic mech-
anism [26] and exchanging it to arginine rendered the enzyme
not only catalytically inactive but also largely unstable (elec-
tronic supplementary material, figure S3; figures 4 and 5).
Thus, our analyses shown below focused mostly on the
TPIIle170Val and TPIIlel70Thr proteins that retained stability and
residual catalytic activity.
3.3. TPIIle170Val and TPIIle170Thr exhibit altered
phosphoenolpyruvate and glyceraldehyde-
3-phosphate binding
We expressed 6x-histidine tagged wild-type human TPI,
TPIIle170Val, TPIIle170Thr and TPILys13Arg in Escherichia coli andpurified the enzymes using metal affinity chromatography.
Far-UV circular dichroism (CD) spectroscopy of the purified
recombinant enzymes showed a similar composition of second-
ary structures, indicating that the mutations did not prevent
folding (electronic supplementary material, figure S2). To deter-
mine the impact of the mutations on the interactions of TPI with
PEP and G3P, we conducted thermal melt assays using the
fluorescent probe SYPRO Orange [30]. In the presence of incre-
mental PEP concentrations, TPI and its mutants exhibited
thermo stabilization, indicating that the proteins bound the
metabolite (figure 3a). Interestingly, TPIIle170Val and TPIIle170Thr
responded more strongly to the presence of PEP (TPIIle170Val
DTm¼ 2.648C, TPIIle170Thr DTm¼ 2.958C) in comparison with a
DTm¼ 2.578C for human wild-type TPI, indicating that the
mutations increased the binding affinity to PEP (figure 3a).
Next, we assessed structural stability in the presence of
the TPI substrate, G3P. This substrate is expected to be con-
stantly metabolized to DHAP (and back) [31,32], and
adding up to 3 mM G3P to wild-type TPI caused a slight
increase in the enzyme’s thermal stability (figure 3b). The
effects of G3P addition to TPIIle170Val were comparable with
that of the wild-type. A much stronger response was however
observed for TPIIle170Thr. This mutant substantially gained
stability in the presence of G3P (figure 3b; DTm ¼ 6.218C at
3 mM G3P, wild-type TPI DTm ¼ 1.688C), indicating that the
binding affinity to this substrate was increased. We speculate
that the increased substrate affinity is facilitated by a hydro-
gen bond between the substrate and the threonine side chain.
Finally, we tested whether protein stability is affected by
PEP in the presence of G3P. In the wild-type form, PEP was
competitive with G3P for binding the enzyme, as expressed
by an increase in thermal stability even at PEP levels lower
than 0.25 mM (figure 3c). Conversely, the increased thermo-
stability mediated by G3P specifically to the TPIIle170Thr
enzyme (figure 3b) was partially lost upon adding PEP
(figure 3c), confirming competitive binding in this mutant
as well. By contrast, TPIIle170Val was resistant to increased
PEP levels (figure 3c), indicating that this metabolite was
no longer competitive for binding. In summary, thermal
shift assays confirmed binding of PEP to TPI. The different
behaviour of the TPIIle170Val and TPIIle170Thr mutants in this
process supports the crystallographic identification of the
binding site to be the catalytic pocket and indicates direct
contact of PEP and G3P with this isoleucine residue.3.4. Inhibitory effects of phosphoenolpyruvate on
triosephosphate isomerase catalysis
Next, we performed enzyme-coupled assays to determine
changes in the catalytic activity of TPI in the mutants as well
as in the presence of PEP. The three mutations affecting resi-
dues located in the catalytic pocket, TPIIle170Val, TPIIle170Thr and
TPILys13Arg, all reduced the catalytic activity of TPI (figure 4a).
The substantial residual activities of 5.9% for TPIIle170Val or
13.1% of TPIIle170Thr indicate that Ile170 is not essential for
TPI’s catalytic function. By contrast, TPILys13Arg exhibited only
catalytic activity around the detection limit of the assay
(approx. 0.2% compared with wild-type level), confirming that
Lys13 is essential for catalysis, as reported earlier [33].
To quantify enzymatic activity for wild-type TPI, TPIIle170Val
and TPIIle170Thr, and to determine the rate of their inhibition by












































Figure 2. The TPI inhibitor PEP and the TPI substrate DHAP have similar interaction sites. (a) Contact distances between TPI and its substrate DHAP, and (b) the
interactions of TPI and PEP in the active site. PEP and DHAP are in contact with similar principal residues. Distances are given in Å. Green balls, phosphate; grey balls,
carbon; red balls, oxygen. The red circles indicate residues in close proximity to the ligand. Illustrations were prepared using LIGPLOT. (c) PEP and DHAP bind similarly
to the TPI active site. Rabbit TPI bound to PEP, overlaid with the location of the TPI substrate DHAP as determined by Jogl et al. [28] as surface representation.
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Figure 3. PEP competes with G3P for binding to human TPI. (a) Thermal stability of human TPI and active-site mutants TPIIle170Val and TPIIle170Thr in the presence of
increasing PEP concentrations. PEP stabilized the three-enzyme species indicative for binding; TPIIle170Val and TPIIle170Thr were stabilized to an increased extent.
(b) Thermal stability of human TPI mutants to increasing G3P concentrations; increased thermal stability of TPIIle170Thr indicated augmented affinity for G3P.






saturation and PEP titration curves for these enzyme species.
The mutant enzymes exhibited lower substrate conversion
rates and saturated at lower concentrations of G3P (Km for
wild-type TPI: 1373 mM, TPIIle170Val: 687 mM and TPIIle170Thr:
303 mM). This indicates that despite its lower activity, the
TPIIle170Thr mutant had higher affinity to the TPI substrate(figure 4b, black curves, from left to right). Next, we titrated
PEP to the reaction operating at maximal activity. In all cases,
a strong and concentration-dependent inhibition of the
enzyme activity was observed. In the case of human wild-
type TPI, 50% of enzyme activity was lost in the presence
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Figure 4. PEP inhibits the catalytic activity of TPI. (a) TPIIle170Val and TPIIle170Thr have reduced catalytic activity, TPILys13Arg is inactive. Enzyme activity expressed as
substrate conversion rate in micromoles per minute and microgram protein. (b) Enzymatic properties of TPI, TPIIle170Val, TPIIle170Thr and their inhibition by PEP.
(c) Substrate titration curves of G3P (black curves, to be read from left to right) on TPI and its mutant enzymes, as well as inhibitor titration curves for PEP










































































Figure 5. Human TPIIle170Val and TPIIle170Thr complement for yeast TPI and are catalytically active. (a) TPI, TPIIle170Val and TPIIle170Thr, but not TPILys13Arg, complement
for yeast TPI1. In a plasmid shuffle experiment, Dtpi1 cells carrying a counterselectable TPI-encoding plasmid were transformed with a centromeric plasmid (mini-
chromosome) encoding the indicated TPI mutants. Transformed cells were then transferred to 5’FOA to induce loss of the counterselectable plasmid. Only cells
containing a functional TPI copy on the minichromosome are viable on glucose media after counterselection. Human TPI, TPIIle170Val and TPIIle170Thr complemented
for a loss of the TPI plasmid, but TPILys13Arg did not. (b) TPI activity in yeast whole-cell extracts. Substrate conversion rates as normalized to total protein content.
TPIIle170Val and TPIIle170Thr have lower activity than wild-type TPI. (c) Increased expression levels of TPIIle170Val and TPIIle170Thr in yeast as revealed by immunoblotting
of whole-cell extracts using a TPI-specific antibody [35]. The amount loaded onto the SDS-PAGE gel was normalized to total protein, comparable loading was








6(figure 4b, blue curves, to be read from right to left). Compared
with pharmacological inhibitors, PEP is thus a relatively low-
affinity inhibitor for TPI. However, this appears biologically
meaningful, as PEP is constantly present at high cellular
levels [14]. A high affinity for PEP would thus render TPI
constantly inactive.
Finally, we observed that the introduced TPI mutations
influenced the PEP sensitivity of TPI. The mutant species exhib-
ited strongly increased IC50 values (TPIIle70Val¼ 1925 mM,
TPIIle170Thr ¼ 1537 mM). This finding supports the crystallo-
graphic result that isoleucine 170 interacts with PEP, rendering
the mutant enzymes in relative terms more PEP-resistant.
3.5. In vivo complementation of triosephosphate
isomerase, TPIIle170Val and TPIIle170Thr
In the next step, we tested whether cells carrying the mutant
enzymes were capable of maintaining metabolism. For this,
we used a yeast strain (MR100 [21]) chromosomally deleted
for yeast TPI1, a direct sequence orthologue of human TPI
catalysing the same reaction, and which is kept viable by
expressing TPI from a 5’FOA-counterselectable URA3 plas-
mid. We introduced human TPI, TPIIle170Val, TPIIle170Thr and
TPILys13Arg into this strain, then selected on 5’FOA media for
cells that had lost the TPI-URA3 plasmid. Yeast strains expres-
sing wild-type TPI, TPIIle170Val and TPIIle170Thr could be
cultured in glucose-containing media, indicating that these
enzymes compensated for the loss of yeast TPI, demonstrating
catalytic activity in vivo. By contrast, yeast cells expressing
TPILys13Arg were not viable, confirming that TPILys13Arg was
not catalytically functional (figure 5a).
Next, TPI activity was measured in cell extracts of the trans-
genic strains. As the total TPI substrate conversion per
microgram protein in the cell extract corresponded to 1.5% com-
pared to the pure enzyme (15.5 mmol NADH min21 mg
protein21), we estimate that TPI accounts for approximately
1.5% of total soluble protein, substantiating that TPI is one of
the most abundant cytoplasmic proteins [34]. Interestingly, we
noted that the total activity of mutant enzymes (TPIIle170Val,
TPIIle170Thr) was, relative to wild-type, significantly lower in
their purified version compared with what we measured
in the cell extracts (figures 4a and 5b). An analysis of TPI
expression levels by immunoblotting using a specific TPI anti-
sera [35] however revealed that mutant TPI is much more
strongly expressed compared with wild-type TPI (figure 5c).
This indicates that cells compensated for a loss of specific TPI
activity by the upregulation of the enzyme abundance.
3.6. Low triosephosphate isomerase activity mediates
elevation in pentose phosphate pathway
metabolite concentrations, oxidant resistance
and heat sensitivity
We have shown previously that reduced activity of TPI causes a
re-configuration of central metabolism, leading to increased flux
of the PPP and increased stress resistance in yeast and C. elegans
[7]. The feedback inhibition of TPI by PEP is therefore expected
to have similar consequences. In bacteria, yeast and mammalian
cells, PEP accumulation is caused by a diminution of PK activity
[11,14,16]. Whereas low PK activity in yeast is correlated
with high respiration rates and superoxide production [14], inhuman cells it is associated with rapid cell proliferation and
cancer [13,36]. Affected by high ROS production, cancer cells
upregulate the allosterically regulated PK isoform PKM2 [37],
which is redox-sensitive and the PKM isoform with lower
catalytic activity [11,13,36]. Moreover, recent results have
demonstrated that cancer cells have higher survival chances
when they lose this gene [15]. This situation causes a block of
the early steps of glycolysis and increases the PPP activity result-
ing in augmented oxidant tolerance of both yeast and
mammalian cells [11,14], indicating that the PK–TPI feedback
loop is important for oxidative stress protection.
As shown above, TPI substrates and PEP bind to the same
structural site and have largely the same contact residues. As a
consequence, mutations that affect PEP binding also affect the
catalytic activity of TPI. This prevents the creation of an ideal in
vivo model where TPI feedback inhibition by PEP would be dis-
rupted while TPI catalytic activity is unaffected. However, the
mutant proteins provide a means of studying the consequences
of specifically lowered TPI activity that mimics the situation of
feedback inhibition. We used the yeast strains expressing
TPIIle170Val and TPIIle170Thr to determine glycolytic and PPP
metabolite concentrations by liquid chromatography tandem
mass spectrometry (LC-MS/MS), adapting our previous pro-
cedures [38,39]. In comparison with the isogenic strain
expressing wild-type TPI, yeast cells expressing both the natu-
rally occurring TPIIle170Val allele and the designed TPIIle170Thr
protein displayed an increased concentration of PPP intermedi-
ates, indicating higher activity of this pathway confirming the
previous results (figure 6a; electronic supplementary material,
figure S4). Moreover, glycolytic intermediates upstream of TPI
were affected, with the strongest measured increase in the con-
centration of the TPI substrate DHAP (figure 6a), reflecting the
partial blockage of glycolysis.
Next, we tested for consequences of expressing the mutant
TPI forms in regard to stress resistance. For this, the transgenic
strains were rendered prototrophic by transformation with the
pHLUM minichromosome [40]. Then, the cells were spotted on
media containing the thiol-oxidizing compound diamide, as
resistance to this compound has previously been shown to be
dependent on PPP activation [7,41], and on media containing
hydrogen peroxide, a naturally occurring oxidant. Resistance
against both oxidants was increased in cells expressing
TPIIle170Val and TPIIle170Thr, with the effects being stronger for
diamide (figure 6b). To address whether this phenotype was
directly depending on the PPP, a similar set of experiments
was then conducted in isogenic strains deleted for the gene
encoding glucose 6-phosphate dehydrogenase (ZWF1), the
first enzyme of the oxidative PPP that is a direct source of
NADPH [42], and SOL3 and SOL4, two paralogous genes
which catalyse the next (non-NADP(H)-dependent) step of
the pathway [43]. The deletion of ZWF1 (on both oxidants)
reduced yeast oxidant tolerances (figure 6b). The deletion of
SOL3 and SOL4 caused weaker effects on H2O2 only (figure
6b). In combination with ZWF1, the protective effects of
TPIIle170Val and TPIIle170Thr were lost, and this phenotype was
affected in combination with SOL3 and SOL4 deletions as
well (figure 6b). This indicates that the TPI-mediated oxidant
protection is dependent on the oxidative PPP, and mainly on
its first NADPH-producing enzyme, the glucose 6-phosphate
dehydrogenase Zwf1p.
Yeast strains with low PK activity are resistant to oxidants
[14] but sensitive to heat [44]. Therefore, we tested whether a
similar behaviour was observed in the TPI mutant strains.
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Figure 6. Low TPI activity increases PPP metabolite load and causes oxidant resistance and heat sensitivity. (a) Concentrations of glycolytic and PPP metabolites in
the human TPIIle170Val and TPIIle170Thr mutants relative to yeast expressing human wild-type TPI. PPP and glycolytic metabolites were quantified by LC-MS/MS. PPP
metabolites are increased in the TPI mutants. Absolute values are given in the electronic supplementary material, figure S4. (b) TPIIle170Val and TPIIle170Thr mediate
increased tolerance to oxidizing agents. Overnight cultures of the indicated yeast strains were diluted to an OD600¼ 3 and spotted onto SC
2His agar plates contain-
ing the oxidants. Glucose 6-phosphate dehydrogenase (Zwf1) encodes the enzyme for the first step in the non-reversible oxidative PPP shunt and produces NADPH.
Its deletion abolishes the oxidant resistance phenotype of cells expressing TPIIle170Val or TPIIle170Thr. Sol3 and Sol4 catalyse the second step of the PPP and their
deletion reduced oxidant resistance on H2O2; a protective effect of TPIIle170Val was detected in Dsol3 yeast while causing H2O2 sensitivity in Dsol4 yeast. (c) TPI
mutants are heat-sensitive. Overnight cultures were diluted to an OD600 ¼ 0.2 and exposed, or not exposed, to 508C for 5 min and growth was monitored for 25 h
after heat exposure. The duration until growth was re-established (lag phase) was used as an inverse indicator for heat resistance. The lag phase was prolonged in





Exponentially growing yeast strains were exposed to 508C for
five minutes or kept at 308C and used to inoculate a fresh cul-
ture. The heat-induced growth delay, calculated using a
model free spline fit [45], was used as a measure of yeast
heat resistance. Yeast cells expressing human TPI welltolerated the heat treatment; however, yeast harbouring
TPIIle170Val and TPIIle170Thr were heat-sensitive, resulting in a
strong delay until growth resumed (figure 6c). Thus, low
TPI activity, despite protecting against oxidants, causes heat
sensitivity. In summary, similar to what has been observed
Table 2. Plasmids used in this study and their deposition ID (http://www.addgene.org).
plasmid name encoded protein application addgene #
p413GPD-hTPI human wild-type TPI1 expression in S. cerevisiae (HIS3, cen) 50719
p413GPD-hTPI Ile170Val human TPI1 Ile170Val expression in S. cerevisiae (HIS3, cen) 50720
p413GPD-hTPI Ile170Thr human TPI1 Ile170Thr expression in S. cerevisiae (HIS3, cen) 50721
p413GPD-hTPI Lys13Arg human TPI1 Lys13Arg expression in S. cerevisiae (HIS3, cen) 50722
pET20b-hTPI human wild-type TPI1 expression and purification in E. coli 50723
pET20b-hTPI Ile170Val human TPI1 Ile170Val expression and purification in E. coli 50724
pET20b-hTPI Ile170Thr human TPI1 Ile170Thr expression and purification in E. coli 50725





in cells with low PK activity [14,44], expressing TPIIle170Val
and TPIIle170Thr increased PPP metabolite concentrations
and mediated oxidant resistance and heat sensitivity.4. Conclusion
The central glycolytic enzyme TPI plays a crucial role in coor-
dinating energy with redox metabolism during stress response
and in cancer. Being the target of a feedback loop initiated by
the pyruvate kinase substrate PEP, dynamic TPI inhibition dis-
tributes metabolites between glycolysis and the PPP [7,14].
Here we present a TPI–PEP co-crystal structure, demonstrat-
ing that PEP directly binds into the catalytic pocket of TPI. In
structure–function studies involving different TPI point
mutations including a rare natural variant (TPIIle170Val [22]),
and two mutants designed on the basis of the crystallographic
findings (TPILys13Arg and TPIIle170Thr), we have demonstrated
that PEP functions as a competitive TPI inhibitor, being able
to interfere with the enzymatic TPI function during catalysis.
Finally, studies with transgenic yeast cells expressing these
human TPI mutants revealed that low TPI activity increases
PPP metabolite concentrations, increased oxidant resistance
and decreased heat tolerance. Hence, the PYK–TPI feedback
loop, leading to the regulation of glycolysis and the PPP to
adapt to oxidative stress conditions, is the consequence of
active-site competitive TPI inhibition by the PK substrate PEP.5. Material and methods
Recombinant TPI expression, enzyme purification, Western
blotting, yeast cultivation and strain generation were con-
ducted according to standard procedures and are described
in the electronic supplementary material. The plasmids gen-
erated in this study have been deposited at Addgene
(http://www.addgene.org) and are listed in table 2.
5.1. Crystallization of triosephosphate isomerase –
phosphoenolpyruvate complex
Native rabbit muscle TPI (TPI, Sigma) was buffer exchanged
into crystallization buffer (20 mM Tris pH: 7.0, 150 mM NaCl,
5 mM MgCl2) with a HiTrap Desalting column and concen-
trated to 10 mg ml21 with a VIVA spin 2 ml concentrator
(MWCO: 10 kDa). PEP was added to the TPI solution to a
final concentration of 5 mM. Crystals were grown at 208Cusing the sitting-droplet vapour diffusion method by
mixing 200 nl of TPI–PEP complex with 200 nl of reservoir
solution (0.1 M MES pH: 6.5, 25% polyethylene glycol
(PEG) 8000). Crystals appeared 1 day after setting up the
crystallization trial and reached the final size in 1 week.
The crystals were transferred briefly into reservoir solution
supplemented with 25% v/v PEG 400 as cryoprotectant
before flash freezing in liquid nitrogen.
5.2. Data collection, structure determination
and refinement
X-ray diffraction data were collected at 100 K from cryopro-
tected crystals at beamline I24 at the Diamond Light Source.
A complete dataset of TPI–PEP crystal was collected to a
resolution of 1.55 Å. The data were processed and scaled
using iMOSFLM and SCALA [46,47], respectively. Molecular
replacement was performed with the CCP4 suite program
PHASER [48] using the rabbit muscle apo TPI (PDB ID: 1R2R)
[27] as the search model. The map identified PEP in the
active site, and the initial model (without ligand) was refined
using REFMAC5 [49]. One protomer was manually adjusted
into the electron density map using COOT and directly placed
in the second protomer based on non-crystallographic
symmetry. The model was refined again with TLS, NCS
(non-crystallographic symmetry) and restrained refinement
using REFMAC5. PEP was finally built into the electron density
map and then refined. A summary of the crystallographic data
and refinement are given in table 1. Figures were generated
using PYMOL.
5.3. Circular dichroism
Recordings of the far-ultraviolet (UV) CD spectrum were used
to verify the native conformation of the purified TPI enzyme
species. The TPI proteins were diluted to a final concentration
of approximately 3.7 mM in 20 mM HEPES (pH 7.5). CD
recordings were performed at 258C on a Jobin Yvon CD6
Dichrograph, as described previously [50]. Three scans were
averaged and base line subtracted using the software provided
by the Jobin Yvon CD6 Dichrograph manufacturer.
5.4. Enzyme activity assays
TPI activity was determined as described previously [21,51].




9transgenic yeast expressing human TPI, or with purified human
TPI recombinantely expressed in E. coli, was determined in an
enzyme-coupled reaction with glycerol 3-phosphate dehydro-
genase. Optical density measurements at 340 nm were used
to detect NADH to NADþ oxidation upon adding the TPI
substrate glyceraldehyde 3-phosphate and recorded in 12 s
intervals in a spectrophotometer (Amersham US 2000). Km
and Ki values were determined by generating saturation
curves with G3P and PEP, respectively.
5.5. Thermal shift assays
The detection of protein thermal unfolding was performed in
96-well plates on an iQ5 real-time PCR cycler (BioRad). The
reaction mix of 100 ml 20 mM HEPES (pH 7.5) contained
approximately 4.5 mM protein, 0.4 ml 500 SYPRO Orange
(Sigma Aldrich) and PEP and/or G3P at the indicated concen-
trations. Thermal unfolding of the proteins was monitored by
increasing the temperature from 25 to 958C in 28C min– 1
steps. Measurements were taken every 0.58C. The resulting
curves were each fitted with a four-parameter log-logistic func-
tion and protein melt points (inflection points) were calculated
using R v. 2.14.1 and the drc package v. 2.3-0. The protein melt
points for each ligand concentration were plotted against the
melt temperature and fitted with equation (5.1).
y ¼ Tmax  x
Kdþ x þ a xþ b: (5:1)
5.6. Oxidant-tolerance tests and growth curves
Oxidant tolerance tests were performed as described earlier
[7] and growth was monitored after 2–3 days of incubation
at 308C. For growth curves, overnight cultures of the indi-
cated yeast strains were diluted to an OD600 ¼ 0.2 in SC
2His
media. Aliquots of the same cultures were incubated for
5 min at the indicated temperatures. Immediately after the
heat shock, the cells were transferred to a 96-well plate
and growth was monitored in a FLUOstar OPTIMA (BMG
Labtech) plate reader for 25 h.
5.7. Sample extraction for metabolomics
Sugar phosphate intermediates were quantified with a pro-
cedure adapted from our earlier work [38,52]. Briefly, 7.5 OD
units of cell suspension were sampled in log phase at anOD600 1.5+0.05 by rapid cold methanol quenching [53] and
then lysed in 200 ml organic extraction buffer (75 : 25
acetonitrile : water, 0.2% formic acid) by three repeated
FastPrep-24 (MP Biomedicals) cycles for 20 s at 6.5 m s21.
The second extraction cycle was performed with 200 ml and
UPLC-grade water. Supernatants from both extraction steps
were combined and the solvent was evaporated in a SpeedVac
concentrator. The dry pellets were resuspended in 100 ml 7%
acetonitrile, centrifuged and metabolite concentrations were
quantified by subsequent LC-MS/MS analysis.5.8. LC-MS/MS measurements
Samples were subjected to LC separation (Agilent 1290) on a
C8 column (Zorbax SB-C8 Rapid Resolution HD, 2.1 
100 mm, 1.8 mm, Agilent; column temperature: 208C, injection
volume: 1 ml). Separation was achieved by isocratic flow at
12% acetonitrile for 3.5 min followed by a gradient to 38%
acetonitrile within 2.5 min. With an additional washing step
(42% acetonitrile, 0.5 min) and re-equilibration to starting con-
ditions, this resulted in a total cycle time of 7.5 min. All buffers
contained 750 mg l21 octylammoniumacetate as ion pairing
reagent. An online coupled triple quadrupole mass spec-
trometer (Agilent 6460) operating in SRM mode was used for
quantification. Individual metabolites were identified by
matching retention time and fragmentation pattern with com-
mercially available standards. SRM transitions, ionization and
fragmentation energies were optimized for each compound
(electronic supplementary material, table S2). Ion source set-
tings are listed in the electronic supplementary material,
table S3. Data analysis was done in the Masshunter Worksta-
tion software package (Agilent). External calibration curves
were measured repeatedly and used to determine absolute
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